Understand the source comparison
Peptides for Psoriasis: Clinical Research Comparison
The table below compares key peptides under investigation for psoriasis based on mechanism, administration route, current research phase, and professional assessment of viability. KPV (lysine-proline-valine) Inhibits NF-kB translocation, reducing IL-17 and TNF
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares key peptides under investigation for psoriasis based on mechanism, administration route, current research phase, and professional assessment of viability.
- KPV (lysine-proline-valine)
- Inhibits NF-kB translocation, reducing IL-17 and TNF-alpha production
- Topical, subcutaneous
- Phase II completed
- 31% PASI reduction at 12 weeks (topical formulation)
- Delivery challenges limit efficacy. Lipid carriers improve penetration but add formulation complexity
- Thymalin (thymic peptide complex)
- Modulates T-cell maturation, increases regulatory T-cell populations
- Subcutaneous, intramuscular
- Observational studies, limited controlled trials
- 18–24% increase in Tregs over 12 weeks
- Batch variability and regulatory hurdles make standardization difficult. Defined synthetic sequences preferred
- LL-37 analogs
- Antimicrobial activity without autoimmune activation
- Topical
- Preclinical
- In vitro reduction of bacterial colonization without dendritic cell activation
- Promising for secondary infection prevention but unproven for plaque reduction
- Beta-defensins (synthetic analogs)
- Restores antimicrobial peptide balance, modulates keratinocyte proliferation
- Mixed results. Some analogs worsen inflammation
- High risk of immune activation. Requires precise structural modification